Colorectal Cancer in Inflammatory Bowel Disease: How to Minimize the Risk
- 1Department of Gastroenterology and Endoscopy, IRCCS San Raffaele Hospital, 20132 Milan, Italy
- 2Department of Gastroenterology and Endoscopy, Faculty of Medicine and Surgery, Vita-Salute San Raffaele University, 20132 Milan, Italy
Abstract
Patients with inflammatory bowel disease (IBD) have a higher risk of developing colorectal cancer (CRC) compared with the general population. This increased risk is mainly related to chronic colonic inflammation and is influenced by factors such as disease duration, disease extent, family history of CRC, and the presence of primary sclerosing cholangitis (PSC). Although the incidence of CRC in IBD has decreased over recent decades, it remains an important cause of disease-related morbidity and mortality. CRC prevention in IBD extends beyond colonoscopic surveillance and includes high-quality endoscopic surveillance, early detection and appropriate treatment of dysplasia, and long-term control of intestinal inflammation through a personalized approach. This review summarizes current evidence on IBD-associated colorectal carcinogenesis and strategies for CRC prevention, with emphasis on risk stratification, optimization of endoscopic surveillance, dysplasia management, treat-to-target strategies and multidisciplinary management.
Related
- Identification of Transcriptional Hippo Response Signature Connecting Inflammatory Bowel Disease and Colorectal Cancer Progression
- Human inflammatory bowel disease-on-a-chip for modelling disease progression, cancer initiation and sex-specific effects
- HLA allele DRB1*01:03: the genetic link to neutralizing IL-10 antibodies in inflammatory bowel disease
- Ustekinumab for Extraintestinal Manifestations in Patients With Inflammatory Bowel Disease: Lessons From the TENOR Real-World Study.
- Identification of a shared PAX5-mediated B-cell regulatory axis in inflammatory bowel disease and rheumatoid arthritis
BibTeX
@article{nassera2026colorectal,
title = {{Colorectal Cancer in Inflammatory Bowel Disease: How to Minimize the Risk}},
author = {Boris Nassera and Lucia Centanni and Ferdinando D’Amico and Alessandra Zilli and Tommaso Lorenzo Parigi and Federica Furfaro and Virginia Solitano and Mariangela Allocca and Silvio Danese},
journal = {Cancers},
year = {2026},
month = oct,
doi = {10.3390/cancers18203272},
url = {https://www.mdpi.com/2072-6694/18/20/3272},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Colorectal Cancer in Inflammatory Bowel Disease: How to Minimize the Risk
AU - Boris Nassera
AU - Lucia Centanni
AU - Ferdinando D’Amico
AU - Alessandra Zilli
AU - Tommaso Lorenzo Parigi
AU - Federica Furfaro
AU - Virginia Solitano
AU - Mariangela Allocca
AU - Silvio Danese
PY - 2026
DA - 2026/10/01
JO - Cancers
DO - 10.3390/cancers18203272
UR - https://www.mdpi.com/2072-6694/18/20/3272
AB - Patients with inflammatory bowel disease (IBD) have a higher risk of developing colorectal cancer (CRC) compared with the general population. This increased risk is mainly related to chronic colonic inflammation and is influenced by factors such as disease duration, disease extent, family history of CRC, and the presence of primary sclerosing cholangitis (PSC). Although the incidence of CRC in IBD has decreased over recent decades, it remains an important cause of disease-related morbidity and mortality. CRC prevention in IBD extends beyond colonoscopic surveillance and includes high-quality endoscopic surveillance, early detection and appropriate treatment of dysplasia, and long-term control of intestinal inflammation through a personalized approach. This review summarizes current evidence on IBD-associated colorectal carcinogenesis and strategies for CRC prevention, with emphasis on risk stratification, optimization of endoscopic surveillance, dysplasia management, treat-to-target strategies and multidisciplinary management.
SN - 2072-6694
ER -